OBJECTIVE: This study aimed to investigate the correlation of midregional pro-atrial natriuretic peptide (MR-proANP) with severity of septic status in patients with ventilator-associated pneumonia (VAP) and the usefulness of MR-proANP for mortality prediction in VAP. DESIGN: Prospective observational cohort study. SETTING: University Hospital. PATIENTS: Seventy-one patients consecutively admitted to ICU who developed VAP. Patients were followed for 28 days after diagnosis, when they were considered survivors. There were no interventions. RESULTS: MR-proANP levels increased from sepsis to severe sepsis and septic shock on D0 and D4 of VAP (0.002 and 0.02 respectively). Median MR-proANP levels on day 0 and day 4 (pmol/L [interquartile range]) were 149.0 (79.8-480.0) and 249.0 (93.6-571.0) in septic patients, 438.5 (229.3-762.0) and 407.5 (197.8-738.0) in severe sepsis, 519.5 (369.5-1282.3) and 632.0 (476.0-1047.5) in septic shock. On day 0 and day 4, MR-proANP levels were significantly higher in non-survivors (525.0 [324.0-957.8] and 679.5 [435.0-879.5], respectively) than in survivors (235.0 [102.0-535.0] and 254.0 [110.0-571.0], respectively; P = 0.004). Univariate logistic regression model for mortality included age, gender, APACHE II score, creatinine, logarithmic transformed MR-proANP (LnMR-proANP). Mortality was directly related to LnMR-proANP on D0 and D4, with odds ratios (OR) of 2.06 (95% CI 1.21-3.51) and 2.63 (1.33-5.23), respectively. In multivariate logistic regression, only LnMR-proANP D0 with OR = 2.35 (1.05-5.26) and LnMR-proANP D4 with OR = 3.76 (1.39-10.18) remained significant. CONCLUSIONS: Our data demonstrated that MR-proANP levels increase progressively with the severity of sepsis and are independent predictors of mortality in VAP.
OBJECTIVE: This study aimed to investigate the correlation of midregional pro-atrial natriuretic peptide (MR-proANP) with severity of septic status in patients with ventilator-associated pneumonia (VAP) and the usefulness of MR-proANP for mortality prediction in VAP. DESIGN: Prospective observational cohort study. SETTING: University Hospital. PATIENTS: Seventy-one patients consecutively admitted to ICU who developed VAP. Patients were followed for 28 days after diagnosis, when they were considered survivors. There were no interventions. RESULTS:MR-proANP levels increased from sepsis to severe sepsis and septic shock on D0 and D4 of VAP (0.002 and 0.02 respectively). Median MR-proANP levels on day 0 and day 4 (pmol/L [interquartile range]) were 149.0 (79.8-480.0) and 249.0 (93.6-571.0) in septic patients, 438.5 (229.3-762.0) and 407.5 (197.8-738.0) in severe sepsis, 519.5 (369.5-1282.3) and 632.0 (476.0-1047.5) in septic shock. On day 0 and day 4, MR-proANP levels were significantly higher in non-survivors (525.0 [324.0-957.8] and 679.5 [435.0-879.5], respectively) than in survivors (235.0 [102.0-535.0] and 254.0 [110.0-571.0], respectively; P = 0.004). Univariate logistic regression model for mortality included age, gender, APACHE II score, creatinine, logarithmic transformed MR-proANP (LnMR-proANP). Mortality was directly related to LnMR-proANP on D0 and D4, with odds ratios (OR) of 2.06 (95% CI 1.21-3.51) and 2.63 (1.33-5.23), respectively. In multivariate logistic regression, only LnMR-proANP D0 with OR = 2.35 (1.05-5.26) and LnMR-proANP D4 with OR = 3.76 (1.39-10.18) remained significant. CONCLUSIONS: Our data demonstrated that MR-proANP levels increase progressively with the severity of sepsis and are independent predictors of mortality in VAP.
Authors: B Müller; E Süess; P Schuetz; C Müller; R Bingisser; A Bergmann; D Stolz; M Tamm; N G Morgenthaler; M Christ-Crain Journal: J Intern Med Date: 2006-12 Impact factor: 8.989
Authors: T A McDonagh; S D Robb; D R Murdoch; J J Morton; I Ford; C E Morrison; H Tunstall-Pedoe; J J McMurray; H J Dargie Journal: Lancet Date: 1998-01-03 Impact factor: 79.321
Authors: M R Cowie; A D Struthers; D A Wood; A J Coats; S G Thompson; P A Poole-Wilson; G C Sutton Journal: Lancet Date: 1997-11-08 Impact factor: 79.321
Authors: Nils G Morgenthaler; Joachim Struck; Mirjam Christ-Crain; Andreas Bergmann; Beat Müller Journal: Crit Care Date: 2004-12-17 Impact factor: 9.097
Authors: Marijke J Vanspauwen; Catharina F M Linssen; Cathrien A Bruggeman; Jan A Jacobs; Marjolein Drent; Dennis C J J Bergmans; Walther N K A van Mook Journal: Crit Care Date: 2011-01-11 Impact factor: 9.097
Authors: Mashael F Alqahtani; Craig M Smith; Scott L Weiss; Susan Dawson; Hantamalala Ralay Ranaivo; Mark S Wainwright Journal: PLoS One Date: 2016-04-18 Impact factor: 3.240
Authors: Thomas P Hellyer; Andrew Conway Morris; Daniel F McAuley; Timothy S Walsh; Niall H Anderson; Suveer Singh; Paul Dark; Alistair I Roy; Simon V Baudouin; Stephen E Wright; Gavin D Perkins; Kallirroi Kefala; Melinda Jeffels; Ronan McMullan; Cecilia M O'Kane; Craig Spencer; Shondipon Laha; Nicole Robin; Savita Gossain; Kate Gould; Marie-Hélène Ruchaud-Sparagano; Jonathan Scott; Emma M Browne; James G MacFarlane; Sarah Wiscombe; John D Widdrington; Ian Dimmick; Ian F Laurenson; Frans Nauwelaers; A John Simpson Journal: Thorax Date: 2014-10-08 Impact factor: 9.102
Authors: Renato Seligman; Luis Francisco Ramos-Lima; Vivian do Amaral Oliveira; Carina Sanvicente; Elyara F Pacheco; Karoline Dalla Rosa Journal: Clinics (Sao Paulo) Date: 2012-11 Impact factor: 2.365